For the intent-to-treat population, more than twice as many subjects in the control group received at least one RBC transfusion during chemotherapy as compared with subjects in the epoetin alfa group (86 [28.1%] vs 41 [12.8%] subjects, respectively). The difference between groups was statistically significant (P < .0001).
epoetin alfa
non–erythropoiesis-stimulating agent (ESA)
number of patients received at least one RBC transfusion during chemotherapy